PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-104.07%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-86.85%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-86.85%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is -0.26%. Seth Klarman would investigate advantages.
-35.35%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
86.85%
EBITDA growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
86.85%
Income change of 86.85% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-35.35%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 7.03%. Seth Klarman would investigate advantages.
87.46%
Income change of 87.46% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
87.46%
Income change of 87.46% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
87.70%
EPS change of 87.70% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
87.70%
Diluted EPS change of 87.70% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.